Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cassava Sciences Inc (SAVA)

Cassava Sciences Inc (SAVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 157,484
  • Shares Outstanding, K 48,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,340 K
  • EBIT $ -111 M
  • EBITDA $ -110 M
  • 60-Month Beta -1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.90

Options Overview Details

View History
  • Implied Volatility 159.54% (+41.56%)
  • Historical Volatility 78.83%
  • IV Percentile 86%
  • IV Rank 14.20%
  • IV High 753.77% on 04/09/25
  • IV Low 61.21% on 07/03/25
  • Expected Move (DTE 1) 0.33 (10.17%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 943
  • Volume Avg (30-Day) 2,672
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 82,157
  • Open Int (30-Day) 82,059
  • Expected Range 2.93 to 3.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Sell
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.28
  • Growth Rate Est. (year over year) +78,146.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +25.14%
on 11/20/25
3.45 -5.51%
on 11/26/25
+0.23 (+7.59%)
since 11/10/25
3-Month
2.04 +59.80%
on 09/15/25
4.98 -34.54%
on 10/16/25
+1.16 (+55.24%)
since 09/10/25
52-Week
1.15 +183.48%
on 04/10/25
4.98 -34.54%
on 10/16/25
+0.37 (+12.80%)
since 12/10/24

Most Recent Stories

More News
Cassava Reports Q3 2025 Financials Results and Provides Business Update

Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Further fortified our strategic capabilities with the appointment of Dawn...

SAVA : 3.26 (+0.62%)
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

SAVA : 3.26 (+0.62%)
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments...

SAVA : 3.26 (+0.62%)
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments...

SAVA : 3.26 (+0.62%)
Cassava Reports Q2 2025 Financials Results and Provides Business Update

Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Recent appointment of experienced...

SAVA : 3.26 (+0.62%)
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disorders Clinical study for simufilam in TSC-related...

SAVA : 3.26 (+0.62%)
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activity Study conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout model First clinical study...

SAVA : 3.26 (+0.62%)
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

SAVA : 3.26 (+0.62%)
Cassava Reports Q1 2025 Financials Results, Provides Business Update

SAVA : 3.26 (+0.62%)
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

SAVA : 3.26 (+0.62%)

Business Summary

Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 3.40
2nd Resistance Point 3.35
1st Resistance Point 3.30
Last Price 3.26
1st Support Level 3.20
2nd Support Level 3.15
3rd Support Level 3.10

See More

52-Week High 4.98
Fibonacci 61.8% 3.52
Last Price 3.26
Fibonacci 50% 3.07
Fibonacci 38.2% 2.61
52-Week Low 1.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar